Clinical Trials
13 trialsNCT04634877 2026-06-05
KEYNOTE-B21
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04269200 2026-06-01
DUO-E
AstraZeneca
Phase 3 Active not recruiting
NCT04956640 2026-05-29
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT03932409 2026-05-08
FIERCE
University of Oklahoma
Phase 1 Active not recruiting
NCT05173987 2026-05-05
KEYNOTE-C93
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03914612 2026-05-04
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01244789 2026-04-13
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Danish Gynecological Cancer Group
Phase 2 Active not recruiting
NCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04644068 2026-02-19
PETRA
AstraZeneca
Phase 1/2 Active not recruiting
NCT06317311 2025-07-25
RUBY-J
GlaxoSmithKline
Phase 2 Active not recruiting
NCT04652076 2024-10-08
GYNET
NETRIS Pharma
Phase 1/2 Active not recruiting
NCT01820858 2024-04-02
EC-01
Huazhong University of Science and Technology
Phase 3 Active not recruiting